MA23079A1 - Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide - Google Patents

Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide

Info

Publication number
MA23079A1
MA23079A1 MA23039A MA23039A MA23079A1 MA 23079 A1 MA23079 A1 MA 23079A1 MA 23039 A MA23039 A MA 23039A MA 23039 A MA23039 A MA 23039A MA 23079 A1 MA23079 A1 MA 23079A1
Authority
MA
Morocco
Prior art keywords
biphosphonates
osteoporosis
treatment
parathyroid hormone
parathyroid
Prior art date
Application number
MA23039A
Other languages
English (en)
French (fr)
Inventor
Dunbar Geddes Ann
Waite Boyce Rogely
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of MA23079A1 publication Critical patent/MA23079A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA23039A 1991-12-17 1992-12-16 Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide MA23079A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17

Publications (1)

Publication Number Publication Date
MA23079A1 true MA23079A1 (fr) 1993-07-01

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23039A MA23079A1 (fr) 1991-12-17 1992-12-16 Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide

Country Status (18)

Country Link
US (1) US5616560A (enExample)
EP (1) EP0618805A1 (enExample)
JP (1) JPH07502507A (enExample)
AU (2) AU3322593A (enExample)
BR (1) BR9206941A (enExample)
CA (1) CA2124792C (enExample)
CZ (1) CZ282889B6 (enExample)
FI (1) FI942884A0 (enExample)
HU (1) HUT68010A (enExample)
IL (1) IL104108A (enExample)
MA (1) MA23079A1 (enExample)
MX (1) MX9207349A (enExample)
NO (1) NO942241D0 (enExample)
NZ (1) NZ246456A (enExample)
RU (2) RU2112515C1 (enExample)
SK (1) SK74594A3 (enExample)
WO (1) WO1993011786A1 (enExample)
ZA (1) ZA929758B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
FR2703590B1 (fr) 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
JPH10505091A (ja) * 1994-09-09 1998-05-19 ザ、プロクター、エンド、ギャンブル、カンパニー 骨粗鬆症用のホスホネート及び副甲状腺ホルモン
KR970705400A (ko) * 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
WO1996019246A1 (en) * 1994-12-19 1996-06-27 Beth Israel Hospital Association Continuous low-dose administration of parathyroid hormone or its agonist
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
WO1996019998A1 (en) * 1994-12-28 1996-07-04 Gador S.A. Bone mass anabolic composition comprising olpadronate
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (en) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
RU2155588C2 (ru) * 1998-10-16 2000-09-10 Общество с ограниченной ответственностью "Институт фармацевтических реактивов РЕФАРМ" Способ увеличения массы костной ткани при переломах
WO2000023594A1 (en) * 1998-10-22 2000-04-27 The General Hospital Corporation BIOACTIVE PEPTIDES AND PEPTIDE DERIVATIVES OF PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHrP)
WO2000032771A1 (en) * 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
KR100864743B1 (ko) 2000-06-20 2008-10-22 노파르티스 아게 비스포스포네이트의 투여 방법
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
EP1439854B1 (en) 2001-07-23 2016-12-14 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
CN1279981C (zh) * 2001-08-17 2006-10-18 诺瓦提斯公司 作为甲状旁腺激素片段的口服递送剂的5－cnac
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
NZ535705A (en) 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
RU2219933C1 (ru) * 2002-07-22 2003-12-27 Волова Лариса Теодоровна Способ стимуляции остеогенеза
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
TWI377958B (en) * 2003-06-26 2012-12-01 Control Delivery Sys Inc In-situ gelling drug delivery system
EP1653985A4 (en) 2003-07-17 2009-08-05 Gen Hospital Corp FORCED PARATHORMON (PTH) ANALOGUE
JP2007501241A (ja) * 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
WO2005018640A1 (en) * 2003-08-20 2005-03-03 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RU2273493C1 (ru) * 2004-10-15 2006-04-10 Валерий Николаевич Зеленков Композиция для профилактики и лечения болезней, вызываемых дефицитом кальция (варианты)
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
RU2481355C2 (ru) * 2007-05-24 2013-05-10 Аблинкс Н.В. Аминокислотные последовательности, направленные на rank-l, и полипептиды, включающие их, для лечения заболеваний и нарушений костей
CA2694667C (en) * 2007-08-01 2018-10-30 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
BR112012013725A2 (pt) 2009-12-07 2017-01-10 Univ Michigan Tech paratormônio de urso preto e métodos de usar o paratormônio de uso preto.
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
BR112012028949B1 (pt) 2010-05-13 2020-11-17 Chugai Seiyaku Kabushiki Kaisha polipeptídeo análogo do hormônio paratireoideo, seu uso e método de produção, bem como ácido nucleico, vetor de expressão, célula e composição farmacêutica
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
JP6618139B1 (ja) 2018-10-29 2019-12-11 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
CZ282889B6 (cs) * 1991-12-17 1997-11-12 Procter And Gamble Pharmaceuticals, Inc. Použití difosfonátů a parathormonu pro výrobu léčiva, které se používá pro léčení osteoporosy

Also Published As

Publication number Publication date
RU2112515C1 (ru) 1998-06-10
FI942884L (fi) 1994-06-16
EP0618805A1 (en) 1994-10-12
FI942884A7 (fi) 1994-06-16
CA2124792C (en) 2000-07-04
NO942241D0 (no) 1994-06-15
NO942241L (enExample) 1994-08-09
NZ246456A (en) 1997-03-24
IL104108A (en) 1999-09-22
WO1993011786A1 (en) 1993-06-24
BR9206941A (pt) 1995-05-02
CZ147794A3 (en) 1994-12-15
HUT68010A (en) 1995-05-29
AU663348B2 (en) 1995-10-05
MX9207349A (es) 1993-12-01
CA2124792A1 (en) 1993-06-24
CZ282889B6 (cs) 1997-11-12
SK74594A3 (en) 1995-01-12
HU9401798D0 (en) 1994-09-28
JPH07502507A (ja) 1995-03-16
ZA929758B (en) 1993-09-10
RU94031209A (ru) 1996-07-27
IL104108A0 (en) 1993-05-13
FI942884A0 (fi) 1994-06-16
AU3322593A (en) 1993-07-19
US5616560A (en) 1997-04-01
RU2104699C1 (ru) 1998-02-20
AU3022692A (en) 1993-06-24

Similar Documents

Publication Publication Date Title
MA23079A1 (fr) Procede pour le traitement de l'osteoporose utilisant des biphosphonates et l'hormone parathyroide
DZ1716A1 (fr) Méthode et mécanisme pour l'enlevement et le traitement des déchets.
FR2682100B1 (fr) Procede et dispositif pour l'epuration biologique des eaux residuaires.
FR2635987B1 (fr) Catalyseurs pour le traitement des effluents gazeux et procede de traitement de ces effluents
FR2667057B1 (fr) Reacteur perfectionne pour le traitement biologique des eaux residuaires.
FR2654936B1 (fr) Procede pour le traitement et l'elimination de dechets medicaux et dispositif pour la mise en óoeuvre du procede.
FR2652759B1 (fr) Catalyseurs pour le traitement des effluents gazeux et procede de traitement de ces effluents.
FR2685652B1 (fr) Procede de traitement des residus de l'incineration de dechets et produits obtenus.
FR2516071B1 (fr) Procede par boues activees pour le traitement d'eaux residuaires
MA21898A1 (fr) Procede de traitement de l'acide phosphorique pour en eliminer certains metaux lourds .
FR2694575B1 (fr) Procede pour le traitement de revetements en mcralz.
FR2644773B2 (fr) Procede et dispositif pour l'epuration d'eaux polluees
FR2563208B1 (fr) Procede de traitement des eaux par l'ozone
MA22278A1 (fr) Procede pour le traitement de troubles respiratoires
FR2674844B1 (fr) Procede et installation de traitement d'epuration de lisiers d'animaux.
FR2619559B1 (fr) Procede pour la regulation des installations d'epuration des eaux residuaires
FR2666080B3 (fr) Composition minerale pour le traitement d'epuration des eaux.
FR2741872B1 (fr) Procede et reacteur biologique pour le traitement de l'eau
FR2621307B3 (fr) Procede d'evacuation et de traitement de boues de decantation provenant de l'epuration d'eaux usees
FR2630727B1 (fr) Procede et dispositif pour le traitement des eaux usees renfermant des nitrites
FR2569423B3 (fr) Procede pour le traitement des cuirs et appareil pour l'execution de ce procede
FR2680123B1 (fr) Procede de traitement de residus fortement polluants pour l'environnement.
FR2679546B1 (fr) Procede de traitement des eaux.
FR2511359B1 (fr) Procede de traitement d'eaux usees par l'ozone
FR2656528B1 (fr) Formule combinee de cimetidine-pirenzepine pour le traitement des ulceres simples de l'estomac et des erosions et procede de traitement.